DOI: 10.36347/sjams.2018.v06i12.075

Pages: 5073-5079

ADA has the same cut-off value for IGT (140-200 mg/dL) but has a lower cut-off value for IFG (100-125 mg/dL) and has additional hemoglobin A1c (HbA1c) based criteria of a level of 5.7% to 6.4% for the definition of prediabetes. Due to progressive nature of prediabetes to diabetes, dual drug therapy produces additive effects, allows the use of submaximal doses, and less side effects of individual agents. Therefore, the present study was designed to study the effect of FDC of Metformin with Pioglitazone Versus FDC of Metformin with Voglibose on Lipid levels as an add-on drug in obese with prediabetes patients whose dyslipidemia status was uncontrolled with metformin alone. Methods: The present study was open, randomized parallel group comparison of two active treatment groups over a period of six months. Sixty-seven patients of either sex in the age group of 30-60 years, suffering from obese with prediabetes, with FBG: 100-125 mg/dl and PPBG: 140-200 mg/dl as per ADA were selected at randomly. The effect of pioglitazone and voglibose were observed on various parameters of Lipid Profile (Total cholesterol, TG, HDL, LDL, VLDL). Results: At the end of 3rd and 6th months it was observed that though both FDC of Metformin with Pioglitazone and FDC of Metformin with Voglibose reduced Lipid levels significantly but Metformin with Pioglitazone caused a statistically significantly greater amount change in Lipid levels as compared with Metformin with Voglibose. Few side effects were observed with Metformin with Voglibose but not with Metformin with Pioglitazone. Conclusions: Though Metformin with Pioglitazone and Metformin with Voglibose were equally effective in lowering Lipid levels yet Metformin with Pioglitazone showed better results in improving dyslipidemia, as compared to Metformin with Voglibose. Pioglitazone had minimal side effects as compared to Metformin with Voglibose.